According to the U.S. Attorney's office in Boston, Pfizer had given some $74,000 to Reuben for a placebo-controlled study of celecoxib (Celebrex) as part of a "multimodal" painkiller regimen for outpatient knee ligament surgery. The study was to enroll 100 patients.

Reuben subsequently reported to Pfizer and in the journal article that 200 patients entered the trial and that the celecoxib regimen was effective.

"In fact, Reuben had not enrolled any patients into that study, and the results reported both to Pfizer and to Anesthesia & Analgesia and, in turn, to the public were wholly m
Medical News: Research Fraud Probe Leads to Criminal Charge - in Public Health & Policy, Ethics from MedPage Today